KiActiv’s digital cardiac rehabilitation programme has significantly reduced heart failure (HF) hospital readmissions while cutting healthcare costs.
The 12-week therapy, which offers HF outpatients personalised daily physical activity regimens to help reduce the risk of cardiac event recurrence upon discharge, has been seen to reduce HF readmissions by 70% after 90 days.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Novel data presented at the 2025 European Society of Cardiology (ESC) conference from a programme at the Liverpool University Hospitals NHS Foundation Trust has also revealed the technology’s potential to improve the mental well-being and quality of life of patients, offering improvements in 74% and 58% of patients, respectively.
Notably, KiActiv also appeared to be superior to standard face-to-face HF cardiac rehabilitation programmes that are generally used by UK hospitals, with patient uptake being six-fold higher than traditional methods.
The positive early outcomes of this programme follow the UK National Institute for Health and Care Excellence’s (NICE) call to conditionally recommend the technology to adult cardiovascular disease outpatients for cardiac rehabilitation in August 2025.
This aligns with the NHS’ recently announced 10-Year Plan, which will see the public health body transition from analogue to digital, utilising technology to empower patients to pursue self-care treatment options.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to Dr Rajiv Sankaranarayanan, consultant cardiologist at the Liverpool University Hospitals NHS Foundation Trust and presenter of KiActiv’s ESC abstract, the technology is believed to be a “world-first” and will support efforts to boost patient rehabilitation rates outside of the hospital setting.
Though the findings from this programme are based on KiActiv’s potential in HF outpatients, the technology’s creator, Tommy Parker, has touted the programme’s efficacy in other long-term conditions such as diabetes, obesity, long Covid and chronic fatigue syndrome.
According to a NICE assessment, the technology will save the NHS £43.40 per £1 spent after ten years – highlighting its potential to reduce treatment costs for the public health service.
Moving forward, KiActiv will work to solidify its footing in the ever-growing digital health market, which GlobalData, parent company of Medical Device Network, valued at $7bn in 2024.
The shift towards patient-centric and convenient outpatient options will likely further drive up the sector’s value, with GlobalData’s analysts forecasting that the market will be worth $22bn by 2034.
Currently, Oracle Health – formerly the Cerner Corporation – dominates the market, making just over 21% of the industry’s total revenue during 2024. This is followed by Otsuka Pharmaceutical and Medtronic, who earned $606m and $496m, respectively, in the same year.
Meanwhile, the UK digital health market was worth $249.6m in 2023.
